AstraZeneca to Formalize MFN Drug Pricing Agreement with Trump
AstraZeneca to Formalize MFN Drug Pricing Agreement with Trump
By John Meyer, Consultant in Business and Finance – Eurasia Business News, October 10, 2025
In a groundbreaking move aimed at reducing prescription drug costs in the United States, AstraZeneca is poised to formalize a Most Favored Nation (MFN) drug pricing agreement with President Donald Trump. This initiative follows a similar arrangement made with Pfizer and is part of a broader strategy to align U.S. drug prices with those in other developed nations.
The agreement, set to be announced today, will see AstraZeneca offering discounted medications through the TrumpRx platform, which facilitates direct-to-consumer sales at significantly lower prices. As part of the deal, the pharmaceutical giant will also invest a staggering $50 billion into U.S. drug manufacturing and research and development. This investment is crucial for AstraZeneca to sidestep potential tariffs that President Trump has threatened against pharmaceutical imports.
AstraZeneca CEO Pascal Soriot is expected to join President Trump in the Oval Office for the announcement, underscoring the administration’s commitment to tackling high drug costs. The MFN agreement aims to bring American drug prices in line with international standards, particularly benefiting low-income patients and Medicaid recipients. Some medications under this agreement could see price reductions of up to 85%, a significant relief for many families struggling with healthcare costs.
The MFN pricing model is designed to ensure that the U.S. does not pay more for certain prescription drugs than the lowest prices paid by other high-income countries, adjusted for GDP. This policy aims to prevent American consumers from overpaying for essential medications, a concern that has long plagued the healthcare system.
This agreement not only aligns with President Trump’s health policy priorities but also promotes “America First” manufacturing strategies, encouraging domestic production of pharmaceuticals. As the healthcare landscape continues to evolve, this partnership between AstraZeneca and the Trump administration could set a precedent for future drug pricing agreements.
As the announcement unfolds, it remains to be seen how this initiative will impact the broader pharmaceutical industry and the millions of Americans who rely on affordable medications.
Stay informed with us—join our community of 170,000 readers and subscribe to our Telegram channel for the latest updates!
Follow us on Telegram, Facebook, and Twitter.
© Copyright 2025 – Eurasia Business News. Article no. 1825
